One hundred years of lung cancer

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 5, 2005, Pages 523-529

  Spiro, Stephen C ^a   Silvestri, Gerard A ^b  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Lung cancer; One hundred years; Staging; Treatment

Indexed keywords

ALKALINE PHOSPHATASE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; METHOTREXATE; NAVELBINE; TAXANE DERIVATIVE; THALIDOMIDE; VINBLASTINE;

CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; HAIR LOSS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SURGERY; MULTIMODALITY CANCER THERAPY; NAUSEA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SMOKING CESSATION; VOMITING;

ANTINEOPLASTIC AGENTS; DEVELOPING COUNTRIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; NEOPLASM STAGING; PNEUMONECTOMY; RADIOTHERAPY; SMOKING;

EID: 24144480937     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200504-531OE     Document Type: Review

References (76)

1. Adler I. Primary malignant growths of the lungs and bronchi. New York: Longmans, Green, and Company; 1912.
2. Witschi H. Profiles in toxicology: a short history of lung cancer. Toxicol Sci 2001;64:4-6.
3. Ochsner A. Corner of history: my first recognition of the relationship of smoking and lung cancer. Prev Med 1973;2:611-614.
4. Doll R, Hill AB. Smoking and carcinoma of the lung. BMJ 1950;2:739-748.
5. U.S. Public Health Service. Surgeon General's advisory committee on smoking and health. Washington. DC: U.S. Government Printing Office; 1964. Publication No. 1103.
6. Gordon T, Crittenden M, Haenszel W. Cancer mortality trends in the United States, 1930-1955. Natl Cancer Inst Monogr 1961;6:131-350.
7. Cancer Statistics Branch Division of Cancer Prevention and Control, National Cancer Institute, National Institutes of Health. Cancer rates and risks. Washington, DC: U.S. Government Printing Office; 1996.
8. Liu BQ, Peto R, Chen ZM, Boreham J, Wu YP, Li JY, Campbell TC, Chen JS. Retrospective proportional mortality study of one million deaths. BMJ 1998;317:1411-1422.
9. Parkin DM, Pisani P, Lopez AD, Masuyer E. At least one in seven cases of cancer is caused by smoking: global estimates for 1995. Int J Cancer 1994;59:494-504.
10. Pisani P, Parkin DM, Bray F, Ferlay J. Esitmates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
11. Pandey M, Mathew A, Nair MK. Global perspective of tobacco habits and lung cancer: a lesson for third world countries. Eur J Cancer Prev 1999;8:271-279.
12. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr. Mortality from smoking in developed countries 1950-2000. In: Indirect estimates from national vital statistics. Oxford, UK: Oxford University Press; 1994.
13. Yang G, Fan L, Tan J, Qi G, Zhang Y, Saniet JM, Taylor CE, Becker K, Xu J. Smoking in China: findings of the 1996 National Prevalence Survey. JAMA 1999;282:1247-1253.
14. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: the Mayo Program. J Occup Med 1986;28:746-750.
15. Marcus P, Bergstralh E, Fagerstrom R, Williams DE, Fontana R, Taylor WF, Prorok DC. Lung cancer mortality in the Mayo Lung Project: impact of extended follow up. J Natl Cancer Inst 2000;92:1308-1316.
16. Bach P, Kelly M, Tate R, McCory D. Screening for lung cancer: a review of the literature. Chest 2003;123:72S-82S.
17. Henschke C, McCauley D, Yankelevitz D, Naidich D, McGuiness G, Miettinen O, Libby D, Pasmantier M, Koizumi J, Altorki N, et al. Early lung cancer detection project: overall design and findings from baseline screening. Lancet 1999;354:99-105.
18. Sone S, Li F, Yang Z, Takashima S, Maruyama Y, Hasegawa M, Wang J, Kawakami S, Honda T. Characteristics of small lung concerns invisible on conventional chest radiography and detected by population based screening using spiral CT. Br J Radiol 2000;73:137-145.
19. Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi T, Tsuchiya R, Kakinuma R, Ohmatsu H, Nagai K, Nishiyama H, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002;20:911-920.
20. Swensen S, Jett J, Sloan J, Midthun D, Hartman T, Sykes A, Aughenbaugh G, Zink F, Hillman S, Noetzel G, et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 2002;165:508-513.
21. Diederich S, Wormanns D, Semik M, Thomas M, Lenzen H, Roos N, Heinde W. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 2002;222:773-781.
22. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Sloan JA, Sykes AM, Aughenbaugh GL, Clemens MA. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003;226:756-761.
23. Mountain C, Dresler C. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-1723.
24. Mountain CF. A new international system for staging lung cancer. Chest 1986;89:225s-233s.
25. Toloza E, Harpole L, McCrory DC. Non-invasive clinical staging of non-small cell lung cancer: radiographic and clinical evaluation of intra- and extra-thoracic disease. Chest 2003;123(1 Suppl):137s-146s.
26. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003;123:l47s-156s.
27. McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JO, Moore EH, Wain JC, Mathisen DJ, Grillo H. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;182:319-323.
28. Nolop K, Rhodes C, Brudin L, Beaney R, Kraus Z, Jones T, Hughes J. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987;60:2682-2689.
29. van Tinteren H, Hoekstra O, Smit E, van den Bergh J, Schreurs A, Stallaert R, van Velthoven P, Comans E, Diepenhorst F, Verboom P, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS Multicentre Randomised Trial. Lancet 2002;359:1388-1393.
30. Detterbeck FC, DeCamp MM, Kohman L, Silvestri GA. Invasive staging: the guidelines. Chest 2003;123:167s-175s.
31. Alberts MW, Bepler G, Hazelton T, Ruckdeschel JC, Williams JH. Practice organization. Chest 2003;123:332s-337s.
32. Brewer LA. Historical notes on lung cancer before and after Graham's successful pneumonectomy in 1933. Am J Surg Pathol 1982;143:650-659.
33. Shields TW, Higgins GA, Keehan RJ. Factors influencing survival after resection for bronchial carcinoma. J Thorac Cadiovasc Surg 1972;64:391-400.
34. Breyer RH, Zippe C, Pharr WF. Thoracotomy in patients over age of seventy years: a ten year experience. J Thorac Cardiovasc Surg 1981;81:187-193.
35. Ginsberg RJ, Hill LD, Eagan RT, Thomas P, Mountain CF, Deslauriers J, Fry WA, Butz RO, Goldberg M, Waters PF, et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 1983;86:654-658.
36. Jensik RJ, Faber LP, Milloy FJ, Monson DO. Segmental resection for lung cancer: a fifteen year experience. J Thorac Cardiovasc Surg 1973;66:563-572.
37. Kirsh MM, Rotman H, Argenta L, Bove E, Cimmino V, Tashian J, Ferguson P, Sloan H. Carcinoma of the lung: results over ten years. Ann Thorac Surg 1976;21:371-377.
38. Carlens E. Mediastinoscopy: a method of inspection and tissue biopsy in the superior mediastinum. Chest 1959;36:343-348.
39. Mountain CF, Carr DT, Anderson WA. A system for the clinical staging of lung cancer. Am J Roentgenol Radium Ther Nucl Med 1974;120:130-138.
40. Le Roux BT. Management of bronchial carcinoma by segmental resection. Thorax 1972;27:70-74.
41. Ginsburg R, Rubinstein L, Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg 1995;60:615-622; discussion 622-623.
42. Gaissert HA, Mathisen DJ, Moncure AC, Hilgenberg AD, Grillo HC, Wain JC. Survival and function after sleeve lobectomy for lung cancer. J Thorac Cardiovasc Surg 1996;111:948-953.
43. Roth J, Fossella F, Komaki R, Ryan M, Putnam J Jr, Lee J, Dhingra H, De Caro L, Chasen M, McGavran M, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
44. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate J, Li S, Roig J, Olazabal A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell cell lung cancer. N Engl J Med 1994;330:153-158.
45. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarie E, Gouva S, et al., for the French Thoracic Cooperative Group. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small cell cell lung cancer. J Clin Oncol 2002;20:247-253.
46. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
47. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
48. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M, and the Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomised study of adjuvant chemotherapy for completely resected Stage I, II, IIIA non-small cell lung cancer. J Natl Cancer Inst 2003;95:1453-1461.
49. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-182.
50. Strauss GM, Herndon J, Maddaus MA, Johnstone DW, Johnson EA, Watson DM. Randomised clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol [Meeting Abstracts] 2004;22:7019.
51. Winton TL, Livingston R, Johnson D, Rigas J, Cormier Y, Butts C, Ding K, Seymour L, Magoski N, Shepherd F. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer (NSCLC) Intergroup JBR.10. J Clin Oncol [Meeting Abstracts] 2004;22:7018.
52. Johnson DH, Einhorn LH, Bartolucci A, Birch R, Omura G, Perez CA, Greco FA. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990;113:33-38.
53. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier M, Douillard J, Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423.
54. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M, CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell cell lung cancer: a randomised multicentre trial. Lancet 1997;350:161-165.
55. Sause W, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran W, Byhardt R, Turrisi A, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
56. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692-2699.
57. Medical Research Council Lung Cancer Working Party. Inoperable non-small cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 1991;63:265-270.
58. Medical Research Council Lung Cancer Working Party. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or single fraction patients with inoperable non-small cell lung cancer (NSCLC) and poor performance status. Br J Cancer 1992;65:934-941.
59. Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled, or oat celled carcinaoma of bronchus: ten year follow up. Lancet 1973;2:63-65.
60. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-895.
61. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992;327:327:1618-1624.
62. Murray N, Coy P, Pater J, Hodson I, Arnold A, Zee B, Payne D, Kostashuk E, Evans W, Dixon P, et al., for the National Cancer Institute of Canada Clinical Trials Group. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer. J Clin Oncol 1993;11:336-344.
63. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer: a randomized study. J Clin Oncol 1997;15:893-900.
64. Work E, Nielsen O, Bentzen S, Fode K, Palshof T, for the Aarhus Lung Cancer Group. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small cell lung cancer. J Clin Oncol 1997;15:3030-3037.
65. Perry M, Herndon J III, Eaton W, Green M. Thoracic radiation therapy added to chemotherapy for small cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol 1998;16:2466-2467.
66. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic review evaluating the timing of thoracic radiation in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004;22:4837-4845.
67. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, for the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-98.
68. Cardenal F, Lopez-Cabrerizo M, Anton A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, Garcia M, Lianes P, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999;17:12-18.
69. Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ, Gower NH, Maslove L, Milroy R, Napp V, Parmar MK, et al., and the Big Lung Trial participants. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59:828-836.
70. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, et al., for the MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) Phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
71. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, et al. Multi-institutional randomized phase II trial of geftinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003;21:2237-2246.
72. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
73. Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, Bezjak A, Tu D, Santabarbara P, Seymour L, for the National Cancer Institute of Canada Clinical Trials Group. Randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy: a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. 2004 ASCO Annual Meeting Proceedings (postmeeting edition). J Clin Oncol 2004:22(Suppl):7022.
74. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
75. Souhami R, Bradbury I, Geddes D, Spiro S, Harper P, Tobias J. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 1985;45:2878-2882.
76. Johnston F. Hippocrates never heard of it: the anatomy of a modern epidemic. Am Surg 1985;51:1-7.